Novo Nordisk shares fell as much as 6.4% in early Friday trade after U.S. President Donald Trump signalled the price of the Danish drugmaker's weight-loss drugs would be lowered.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback